JP2018537535A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537535A5
JP2018537535A5 JP2018549403A JP2018549403A JP2018537535A5 JP 2018537535 A5 JP2018537535 A5 JP 2018537535A5 JP 2018549403 A JP2018549403 A JP 2018549403A JP 2018549403 A JP2018549403 A JP 2018549403A JP 2018537535 A5 JP2018537535 A5 JP 2018537535A5
Authority
JP
Japan
Prior art keywords
compound according
ring
optionally substituted
fluorine
aliphatic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537535A (ja
JP6810156B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/065865 external-priority patent/WO2017100601A1/en
Publication of JP2018537535A publication Critical patent/JP2018537535A/ja
Publication of JP2018537535A5 publication Critical patent/JP2018537535A5/ja
Application granted granted Critical
Publication of JP6810156B2 publication Critical patent/JP6810156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549403A 2015-12-09 2016-12-09 Pad4のアザベンゾイミダゾール阻害剤 Active JP6810156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264919P 2015-12-09 2015-12-09
US62/264,919 2015-12-09
PCT/US2016/065865 WO2017100601A1 (en) 2015-12-09 2016-12-09 Aza-benzimidazole inhibitors of pad4

Publications (3)

Publication Number Publication Date
JP2018537535A JP2018537535A (ja) 2018-12-20
JP2018537535A5 true JP2018537535A5 (https=) 2020-01-23
JP6810156B2 JP6810156B2 (ja) 2021-01-06

Family

ID=59013635

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549403A Active JP6810156B2 (ja) 2015-12-09 2016-12-09 Pad4のアザベンゾイミダゾール阻害剤

Country Status (17)

Country Link
US (1) US9765093B2 (https=)
EP (1) EP3386505B1 (https=)
JP (1) JP6810156B2 (https=)
KR (1) KR102683681B1 (https=)
CN (1) CN108601770B (https=)
AR (1) AR107030A1 (https=)
AU (1) AU2016366405A1 (https=)
BR (1) BR112018011633A2 (https=)
CA (1) CA3007954A1 (https=)
EA (1) EA201891347A1 (https=)
ES (1) ES2830353T3 (https=)
IL (1) IL259796A (https=)
MX (1) MX2018006700A (https=)
SG (1) SG11201804671SA (https=)
TW (1) TW201726689A (https=)
UY (1) UY37017A (https=)
WO (1) WO2017100601A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6926126B2 (ja) 2016-02-23 2021-08-25 パドロック・セラピューティクス・インコーポレイテッドPadlock Therapeutics, Inc. Pad4のヘテロアリール阻害剤
KR102398941B1 (ko) 2016-07-27 2022-05-17 패들락 테라퓨틱스, 인코포레이티드 Pad4의 공유결합성 억제제
JP7118951B2 (ja) 2016-09-12 2022-08-16 パドロック・セラピューティクス・インコーポレイテッド Pad4のヘテロアリール阻害剤
CN112789087B (zh) * 2018-08-08 2024-08-13 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
EP3833671B1 (en) 2018-08-08 2022-08-24 Bristol-Myers Squibb Company Substituted thienopyrroles as pad4 inhibitors
AU2019319835A1 (en) 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes
WO2020033488A1 (en) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Substituted benzimidazoles as pad4 inhibitors
EP4100405A1 (en) * 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
EP4143189A1 (en) 2020-04-30 2023-03-08 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
TW202241884A (zh) 2020-12-22 2022-11-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2022140428A2 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025199042A1 (en) * 2024-03-18 2025-09-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Methods for treating severe tuberculosis
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
EP2358202B1 (en) * 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
RS55684B1 (sr) * 2012-07-26 2017-07-31 Glaxo Group Ltd 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori

Similar Documents

Publication Publication Date Title
JP2018537535A5 (https=)
JP2018021051A5 (https=)
JP2019537570A5 (https=)
JP2013542261A5 (https=)
JP2016534063A5 (https=)
JP2019516739A5 (https=)
JP2012513416A5 (https=)
JP2014508752A5 (https=)
JP2016518437A5 (https=)
JP2014511892A5 (https=)
JP2017528503A5 (https=)
JP2017504635A5 (https=)
JP2014506907A5 (https=)
JP2016528301A5 (https=)
JP2016527217A5 (https=)
JP2016503797A5 (https=)
JP2017517538A5 (https=)
JP2015500223A5 (https=)
JP2020507589A5 (https=)
JP2017501236A5 (https=)
JP2015508092A5 (https=)
JP2019535723A5 (https=)
JP2019505529A5 (https=)
JP2016522254A5 (https=)
JP2019520344A5 (https=)